Significance of Fluorescence Colposcopy With Autofluorescence Imaging for Cervical Cancer

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified May 2013 by Asan Medical Center
Information provided by (Responsible Party):
Jeong-Yeol Park, Asan Medical Center Identifier:
First received: May 14, 2013
Last updated: NA
Last verified: May 2013
History: No changes posted

Clinical Trial to access Significance of fluorescence colposcopy with autofluorescence imaging for the screening of cervical cancer

Cervical Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Clinical Trial to Access Significance of Fluorescence Colposcopy With Autofluorescence Imaging for the Screening of Cervical Cancer

Resource links provided by NLM:

Further study details as provided by Asan Medical Center:

Primary Outcome Measures:
  • fluorescence colposcopic result [ Time Frame: 2weeks after fluorescence colposcopy ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 80
Study Start Date: May 2013
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Detailed Description:
  1. Perform pelvic vaginal exam of the subjective to know symptom, illness history, physical exam and basal state before fluorescence colposcopy.
  2. Observe acetowhite epithelium and perform biopsy at suspicious lesion during fluorescence colposcopy.
  3. Perform fluorescence colposcopy again after biopsy and confirm extraordinary reaction.
  4. After 1~2weeks follow up the subjective at opd and confirm biopsy result.

Ages Eligible for Study:   20 Years to 65 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

tertiary center


Inclusion Criteria:

  1. age : 20-65 years
  2. abnormal cervical papanicolaou smear , no other specific cervical disease
  3. subject to colposcopic biopsy or LEEP
  4. signed voluntarily to informed concents with full knowledge after explanation abot objective, method, contents

Exclusion Criteria:

  1. pregnant women
  2. porphyria
  3. severe cervical bleeding
  4. genital chlamydia, gonorrhea infection
  5. other drug user with possible interaction (e.g. photosensitizer)
  6. no informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01854983

Contact: Jeong-Yeol Park, M.D., Ph.D. +82-2-3010-3628

Korea, Republic of
Asan Medical Center Not yet recruiting
Seoul, Korea, Republic of, 138-736
Contact: Jeong-Yeol Park, M.D., Ph.D.    +82-2-3010-3628   
Sponsors and Collaborators
Asan Medical Center
Study Chair: Jeong-Yeol Park, M.D., Ph.D. Asan Medical Center
  More Information

No publications provided

Responsible Party: Jeong-Yeol Park, clinical assistant professor, Asan Medical Center Identifier: NCT01854983     History of Changes
Other Study ID Numbers: 2012-0693
Study First Received: May 14, 2013
Last Updated: May 14, 2013
Health Authority: South Korea: Institutional Review Board

Keywords provided by Asan Medical Center:
fluorescence colposcopy
cervical cancer

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Genital Diseases, Female
Genital Neoplasms, Female
Neoplasms by Site
Urogenital Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Uterine Neoplasms processed this record on October 23, 2014